Vmbook Online ordering

Biodelivery Sciences Internati

BioDelivery Sciences International (BDSI) is a specialty pharmaceutical company focused on developing and commercializing innovative and advanced therapies for chronic conditions, including pain management and addiction disorder. The company's portfolio includes a variety of products, both FDA-approved and in development, that utilize their proprietary BioErodible MucoAdhesive (BEMA) technology. Some of BDSI's most notable products include:

1. BELBUCA (buprenorphine) Buccal Film: An FDA-approved medication for the management of moderate to severe chronic pain in adults who require around-the-clock, long-term opioid treatment.

2. Symproic (naldemedine) Tablets: Approved for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.

3. Cotempla XR-ODT (methylphenidate) Extended-release Orally Disintegrating Tablets: Approved for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents (ages 6-17).

4. Oxytrol for Women (oxybutynin) Transdermal System: A prescription medication used to treat overactive bladder (OAB) in women.

BioDelivery Sciences International is a publicly traded company listed on the NASDAQ stock exchange with the ticker symbol "BDSI". As of February 2023, the company's market capitalization is approximately $275M, with over 52M shares outstanding. Investors are encouraged to conduct their own thorough research and consult a financial advisor when making investment decisions related to stocks and other securities.